Siirry sisältöön

Asuragen QuantideX BCR-ABL tests

qPCR molecular methods to help advance our understanding of cancer

The Asuragen Oncology portfolio uses proprietary molecular chemistry and informatics solutions to deliver critical clinical research insights that drive the evolution of therapy, patient monitoring and precision medicine.


The QuantideX® qPCR BCR-ABL IS Kit is intended for chronic myeloid leukemia (CML) monitoring. It’s a qPCR-based in vitro Diagnostic test for the quantitation of BCR-ABL1 and ABL1 transcripts in total RNA from whole blood of diagnosed t(9;22) positive CML patients expressing e13a2 and/or e14a2 fusion transcripts.

QuantideX qPCR BCR-ABL minor

The QuantideX qPCR BCR-ABL minor Kit, an in vitro diagnostic (IVD) assay, enables ultra-sensitive detection of BCR-ABL1 minor breakpoint (e1a2) transcripts from whole blood specimens.

  • Sensitivity 0.002% IS (MR4.7)
  • Data analysis software eliminates manual intervention to provide automated calculations and streamlined reporting
  • Direct reporting on the International Scale (IS): No sample exchange or conversion factor calculations required
  • Optimized Workflow
    • Multiplexed assay design that amplifies and detects both fusion and control gene in the same reaction
    • All-inclusive reagents sourced and Quality Controlled together from a single vendor
    • Pre-mixed tubes leading to fewer pipetting steps in the mastermix preparation
  • Armored RNA based standards providing true RNA quantification for a quantitative RNA assay
  • Ultra-sensitive Limit of Detection (LOD): Log reduction of 4.61 (0.0025% ratio)
  • Included software provides automated calculation of BCR-ABL1/ABL1 % ratio
  • Shares a common workflow with the QuantideX qPCR BCR-ABL IS Kit to reduce training burden and streamline test implementation

Product is available in the following countries:

  • Finland
  • Estonia
  • Latvia
  • Lithuania

Links and documents

Manufacturer’s product page